Biotherapeutics and Biosimilars. (WHO Drug Information Vol. 29, No. 2, 2015)
(2015; 4 pages)

Resumen

Advances in biotechnology have enabled scientists to produce biological medicinal products that provide new treatment options for a wide range of diseases, including life-threatening ones. However, these complex medicines are expensive to develop and produce, and their high cost potentially affects equitable access to them. Biosimilars – products that are very similar to already approved biotherapeutic products – could make this new generation of medicines available more widely at a more affordable cost to health systems. This article describes some recent developments in global efforts to create regulatory pathways and naming systems for biotherapeutics, including biosimilars.

 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019